Clostridium difficile-associated disease in the new millennium: "The perfect storm" has arrived

Infectious Diseases in Clinical Practice

Volumn 15, Issue 5, 2007, Pages 299-315

  Owens Jr , Robert C ^a,b   Valenti, August J ^a,b  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BACITRACIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLESTIPOL; COLESTYRAMINE; FUSIDIC ACID; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; MDX 066; MDX 1388; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RAMOPLANIN; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; RIFAXIMIN; TEICOPLANIN; TIACUMICIN B; TINIDAZOLE; TOLEVAMER; TOXOID; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL RADIOGRAPHY; ALGORITHM; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL SPORE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE; COLON RESECTION; COLONOSCOPY; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; HOSPITAL HYGIENE; HUMAN; HYPOKALEMIA; INFECTION CONTROL; LABORATORY TEST; MONOTHERAPY; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PATIENT SAFETY; RECURRENT DISEASE; REPEATED DRUG DOSE; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; STOMACH ACID; TASTE DISORDER;

EID: 34548667438     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/IPC.0b013e3180686491     Document Type: Review

References (142)

1. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758-764.
2. Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531-534.
3. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol. 2006;44:2785-2791.
4. Hogenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis 1. N Engl J Med. 2006;355:2418-2426.
5. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12:409-415.
6. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466-472.
7. Wilcox MH, Freeman J. Epidemic Clostridium difficile. N Engl J Med. 2006;354:1199-1203.
8. Nielsen ND, Layton BA, McDonald LC, et al. Changing epidemiology of Clostridium difficile-associated disease: experience and perception of infectious diseases consultants. Infect Dis Clin Pract. 2006;14:296-302.
9. Wanahita A, Goldsmith EA, Marino BJ, et al. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med. 2003;115:543-546.
10. Freiler JF, Durning SJ, Ender PT. Clostridium difficile small bowel enteritis occurring after total colectomy. Clin Infect Dis. 2001;33:1429-1431.
11. Nash SV, Bourgeault R, Sands M. Colonic disease associated with a positive assay for Clostridium difficile toxin: a retrospective study. J Clin Gastroenterol. 1997;25:476-479.
12. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med. 2001;161:525-533.
13. Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16:459-477.
14. Johnson S, Kent SA, O'Leary KJ, et al. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med. 2001;135:434-438.
15. Cloud J, Kelly CP. Update on Clostridium difficile associated disease. Curr Opin Gastroenterol. 2007;23:4-9.
16. Gerding DN. New definitions will help, but cultures are critical for resolving unanswered questions about Clostridium difficile. Infect Control Hosp Epidemiol. 2007;28:113-115.
17. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363-372.
18. McEllistrem MC, Carman RJ, Gerding DN, et al. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005;40:265-272.
19. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased f luoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273-280.
20. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173:1037-1042.
21. Eggertson L. Quebec strain of C. difficile in 7 provinces. CMAJ. 2006;174:607-608.
22. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-1597.
23. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine. 2004;22:848-856.
24. Alfa MJ, Kabani A, Lyerly D, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38:2706-2714.
25. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18:247-263.
26. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
27. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441.
28. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-1084.
29. Fawley WN, Underwood S, Freeman J, et al. Measurement of toxin production by Clostridium difficile. Lancet. 2006;367:982-983.
30. Barbut F, Decre D, Lalande V, et al. Clinical features of Clostridium difficile - associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol. 2005;54:181-185.
31. Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1201-1205.
32. Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med. 2006;166:2518-2524.
33. Wilcox MH, Fawley WN. Hospital disinfectants and spore formation by Clostridium difficile. Lancet. 2000;356:1324.
34. Underwood S, Stephenson K, Fawley WN, et al. Effects of hospital cleaning agents on spore formation by N American and UK outbreak Clostridium difficile strains; 2005.
35. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204-210.
36. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1-15.
37. Pepin J, Saheb N, Coulombe MA, et al. Emergence of f luoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-1260.
38. Gerding DN. Clindamycin, cephalosporins, f luoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis. 2004;38:646-648.
39. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989-2995.
40. Mulligan ME, Miller SD, McFarland LV, et al. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis. 1993;16(suppl 4):S239-S244.
41. Johal SS, Lambert CP, Hammond J, et al. Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea. J Clin Pathol. 2004;57:973-979.
42. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:1027-1034.
43. Bartlett JG. New drugs for Clostridium difficile infection. Clin Infect Dis. 2006;43:428-431.
44. Bingley PJ, Harding GM. Clostridium difficile colitis following treatment with metronidazole and vancomycin. Postgrad Med J. 1987;63:993-994.
45. Mohr J. Outbreak of Clostridium difficile infection and gatif loxacin use in a long-term care facility. Clin Infect Dis. 2004;39:875-876.
46. Owens RC. Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006;26:299-311.
47. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on f luoroquinolones. Clin Infect Dis. 2005;41(suppl 2)S144-S157.
48. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatif loxacin use. Clin Infect Dis. 2004;38:640-645.
49. Biller P, Shank B, Lind L, et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol. 2007;28:198-201.
50. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003;51:1339-1350.
51. McCusker ME, Harris AD, Perencevich E, et al. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis. 2003;9:730-733.
52. Dhalla IA, Mamdani MM, Simor AE, et al. Are broad-spectrum f luoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother. 2006;50:3216-3219.
53. Sambol SP, Merrigan MM, Tang JK, et al. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis. 2002;186:1781-1789.
54. Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med. 1998;128:989-995.
55. Kutty P, Benoit S, Woods C, et al. Emerging Clostridium difficile-associated disease in the community and the role of non-antimicrobial risk factors. In: Program and Abstracts of the 44th Annual Meeting of the Infectious Diseases Society of America; October 13, 2006; Toronto, Canada. Abstract LB-28.
56. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171:33-38.
57. Al-Tureihi FI, Hassoun A, Wolf-Klein G, et al. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 2005;6:105-108.
58. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54:243-245.
59. Lowe DO, Mamdani MM, Kopp A, et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis. 2006;43:1272-1276.
60. Rammer M, Kirchgatterer A, Hobling W, et al. Lansoprazole-associated collagenous colitis: a case report. Z Gastroenterol. 2005;43:657-660.
61. Thomson RD, Lestina LS, Bensen SP, et al. Lansoprazole-associated microscopic colitis: a case series. Am J Gastroenterol. 2002;97:2908-2913.
62. Yuan S, Reyes V, Bronner MP. Pseudomembranous collagenous colitis. Am J Surg Pathol. 2003;27:1375-1379.
63. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189-193.
64. Kim KH, Fekety R, Batts DH, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981;143:42-50.
65. Huang SS, Datta R, Platt R. Risk of acquiring antibiotic-resistant bacteria from prior room occupants. Arch Intern Med. 2006;166:1945-1951.
66. Samore MH, Venkataraman L, DeGirolami PC, et al. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med. 1996;100:32-40.
67. Bliss DZ, Johnson S, Savik K, et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med. 1998;129:1012-1019.
68. Leischner J, Johnson S, Sambol S, et al. Effect of alcohol hand gels and chlorhexidine hand wash in removing spores of Clostridium difficile from hands. In: Program and Abstracts of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; December 2005; Washington, DC. Abstract KB-29.
69. Boyce JM, Ligi C, Kohan C, et al. Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs. Infect Control Hosp Epidemiol. 2006;27:479-483.
70. Centers for Disease Control and Prevention. Information about a new strain of Clostridium difficile. Available at: http://www.cdc.gov/ncidod/ dhqp/id_CdiffFAQ_newstrain.html. Accessed August 21, 2006.
71. Wilcox MH. Cleaning up Clostridium difficile infection. Lancet. 1996;348:767-768.
72. Wilcox MH, Fawley WN, Parnell P. Value of lysozyme agar incorporation and alkaline thioglycollate exposure for the environmental recovery of Clostridium difficile. J Hosp Infect. 2000;44:65-69.
73. Rutala WA, Weber DJ. Uses of inorganic hypochlorite (bleach) in health-care facilities. Clin Microbiol Rev. 1997;10:597-610.
74. Wilcox MH, Fawley WN, Wigglesworth N, et al. Detergent versus hypochlorite cleaning and Clostridium difficile infection. J Hosp Infect. 2004;56:331.
75. Apisarnthanarak A, Zack JE, Mayfield JL, et al. Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile. Clin Infect Dis. 2004;39:601-602.
76. Kaatz GW, Gitlin SD, Schaberg DR, et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol. 1988;127:1289-1294.
77. Mayfield JL, Leet T, Miller J, et al. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis. 2000;31:995-1000.
78. Davey P, Brown E, Fenelon L, et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis. 2006;12:211-216.
79. Valenti AJ. The role of infection control and hospital epidemology in the optimization of antibiotic use. In: Owens RC Jr, Ambrose PG, Nightingale CH, eds. Antibiotic Optimization: Concepts and Strategies in Clinical Practice. 1st ed. New York: Marcel Dekker; 2005:209-259.
80. Eggertson L. Quebec puts up 20 million dollars for C. difficile fight. CMAJ. 2005;172:622.
81. Friedenberg F, Fernandez A, Kaul V, et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum. 2001;44:1176-1180.
82. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious diseases society of america and the society for healthcare epidemiology of america guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159-177.
83. Palmer DA, Bauchner H. Parents' and physicians' views on antibiotics. Pediatrics. 1997;99:E6.
84. Watson RL, Dowell SF, Jayaraman M, et al. Antimicrobial use for pediatric upper respiratory infections: reported practice, actual practice, and parent beliefs. Pediatrics. 1999;104:1251-1257.
85. Davey P, Brown E, Fenelon L, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2005;(4):CD003543.
86. de LF, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 1992;36:2192-2196.
87. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother. 2004;54:211-216.
88. Dudley MN, McLaughlin JC, Carrington G, et al. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med. 1986;146:1101-1104.
89. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology. 1985;89:1038-1045.
90. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2005;(1):CD004610.
91. Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for mom? Clin Infect Dis. 2005;40:1598-1600.
92. Pepin J, Routhier S, Gagnon S, et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006;42:758-764.
93. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006;43:421-427.
94. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother. 1995;36:673-679.
95. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med. 1989;86:15-19.
96. Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis. 2006;43:547-552.
97. Freeman J, Stott J, Baines SD, et al. Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother. 2005;56:988-989.
98. Pelaez T, Alcala L, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother. 2002;46:1647-1650.
99. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;245:267-272.
100. Longo WE, Mazuski JE, Virgo KS, et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004;47:1620-1626.
101. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49:640-645.
102. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;53:882-884.
103. Thorpe CM, Gorbach SL. Update on Clostridium difficile. Curr Treat Options Gastroenterol. 2006;9:265-271.
104. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769-1775.
105. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol. 2005;54:101-111.
106. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1985;80:867-868.
107. Buggy BP, Fekety R, Silva J Jr. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol. 1987;9:155-159.
108. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580-585.
109. Liacouras CA, Piccoli DA. Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol. 1996;22:186-189.
110. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95:3283-3285.
111. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1:1156-1160.
112. Seal D, Borriello SP, Barclay F, et al. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol. 1987;6:51-53.
113. Nakai A, Nishikata M, Matsuyama K, et al. Drug interaction between simvastatin and cholestyramine in vitro and in vivo. Biol Pharm Bull. 1996;19:1231-1233.
114. Taylor NS, Bartlett JG. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis. 1980;141:92-97.
115. Wilcox MH. Treatment of Clostridium difficile infection. J Antimicrob Chemother. 1998;41(suppl C):41-46.
116. Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ. 2005;173:167-170.
117. D'Souza AL, Rajkumar C, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002;324:1361.
118. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812-822.
119. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913-1918.
120. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L rhamnosus GG. Clin Infect Dis. 2004;38:62-69.
121. Lherm T, Monet C, Nougiere B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med. 2002;28:797-801.
122. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis. 2005;41:1559-1568.
123. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol. 2003;41:5340-5343.
124. Mogg GA, George RH, Youngs D, et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br J Surg. 1982;69:137-139.
125. Owens RC Jr, Loew B, Soni S, et al. Impact of interventions on non-evidence based treatment strategies during an outbreak of Clostridium difficile-associated disease due to BI/NAP1. In: Program and Abstracts of the 44th Annual Infectious Diseases Society of America, Toronto, Ontario, CA; 2006:60. Abstract 687.
126. Olson MM, Shanholtzer CJ, Lee JT Jr. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol. 1994;15:371-381.
127. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med. 1992;117:297-302.
128. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397.
129. Gerard L, Garey KW, Dupont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections 1. Expert Rev Anti Infect Ther. 2005;3:201-211.
130. Gerding DN, Johnson S, Osmolski JR, et al. In vitro activity of ramoplanin, rifalazil, rifaximin, metronidazole, and vancomycin against 110 unique toxigenic Clostridium difficile clinical isolates. [Abstr. E-1439]. In: Program and Abstracts of the 45th Annual Conference on Antimicrobial Agents and Chemotherapy. 2005 Dec 16-19; Washington D.C.: American Society for Microbiology.
131. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846-848.
132. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000;343:1925-1932.
133. Jodlowski TZ, Oehler R, Kam LW, et al. Emerging therapies in the treatment of Clostridium difficile-associated disease. Ann Pharmacother. 2006;40:2164-2169.
134. Citron DM, Tyrrell KL, Warren YA, et al. In vitro activities of tinidazole and metronidazole against Clostridium difficile, Prevotella bivia and Bacteroides fragilis. Anaerobe. 2005;11:315-317.
135. Louie TJ. Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment options. Clin Infect Dis. 2006;42:765-767.
136. Ackermann G, Loff ler B, Adler D, et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004;48:2280-2282.
137. Freeman J, Baines SD, Jabes D, et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother. 2005;56:717-725.
138. Barker RH Jr, Dagher R, Davidson DM. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther. 2006;24:1525-1534.
139. Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis. 2006;43:411-420.
140. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun. 2006;74:6339-6347.
141. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology. 2005;128:764-770.
142. Press Release: Genzyme announces data from first phase 3 study of tolevamer in patients with C. difficile associated diarrhea. Available at: http://www.genzyme.com/corp/media/GENZ%20PR-070607.asp. Accessed July 16, 2007.